North America Respiratory Syncytial Virus Vaccines Market Size & Outlook
Related Markets
North America respiratory syncytial virus vaccines market highlights
- The North America respiratory syncytial virus vaccines market generated a revenue of USD 1,000.8 million in 2024.
- The market is expected to grow at a CAGR of 42.5% from 2025 to 2030.
- In terms of segment, passive immunization was the largest revenue generating type in 2024.
- Preventive Vaccines is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 1,000.8 million |
| Market revenue in 2030 | USD 8,180.9 million |
| Growth rate | 42.5% (CAGR from 2025 to 2030) |
| Largest segment | Passive immunization |
| Fastest growing segment | Preventive Vaccines |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Passive Immunization, Preventive Vaccines |
| Key market players worldwide | AstraZeneca PLC, Sanofi SA, GSK PLC, Pfizer Inc, Moderna Inc, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, Merck & Co., Inc. |
Other key industry trends
- In terms of revenue, North America region accounted for 28.5% of the global respiratory syncytial virus vaccines market in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 8,180.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Respiratory Syncytial Virus Vaccines Market Scope
Respiratory Syncytial Virus Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Blue Lake Biotechnology | View profile | 11-50 | Athens, Georgia, United States, North America | https://www.bluelakebiotechnology.com |
| Codagenix | View profile | 1-10 | Farmingdale, New York, United States, North America | http://codagenix.com |
| Meissa Vaccines | View profile | 11-50 | San Francisco, California, United States, North America | http://www.meissavaccines.com/ |
| Icosavax | View profile | 51-100 | Seattle, Washington, United States, North America | http://www.icosavax.com/ |
| Merck & Co., Inc. | View profile | - | - | - |
| Moderna Inc | View profile | 5600 | 200 Technology Square, Cambridge, MA, United States, 02139 | https://www.modernatx.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
North America respiratory syncytial virus vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to respiratory syncytial virus vaccines market will help companies and investors design strategic landscapes.
Passive immunization was the largest segment with a revenue share of 102.26% in 2024. Horizon Databook has segmented the North America respiratory syncytial virus vaccines market based on passive immunization, preventive vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure. In 2023, the U.S. Centers for Disease Control and Prevention (CDC) introduced a national campaign to raise awareness about RSV and available vaccines, boosting adoption rates.
However, in June 2024, the CDC narrowed its recommendations, advising RSV vaccination primarily for adults aged 75 and older, and those aged 60–74 with specific medical conditions.
Reasons to subscribe to North America respiratory syncytial virus vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America respiratory syncytial virus vaccines market databook
-
Our clientele includes a mix of respiratory syncytial virus vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America respiratory syncytial virus vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into North America respiratory syncytial virus vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America respiratory syncytial virus vaccines market size, by country, 2018-2030 (US$M)
North America Respiratory Syncytial Virus Vaccines Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
